Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03404570 · ClinicalTrials.gov registry record · Phase 2

Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

A Phase 2 study of Palmar Hyperhidrosis, sponsored by Atacama Therapeutics.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
3
Study locations

NCT03404570 is a Phase 2 study of Palmar Hyperhidrosis that has completed, run by Atacama Therapeutics. The registered enrollment target is 60 participants. The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03404570, a Phase 2 study of Palmar Hyperhidrosis, has completed, sponsored by Atacama Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
3
Study locations

Study Summary

This is a pilot exploratory study to evaluate the safety and efficacy of TC-5214 in subjects with palmar hyperhidrosis.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Dexmecamylamine HCl

Study Locations (3)

California

  • Site 02 - San Diego

Missouri

  • Site 03 - St Louis

Virginia

  • Site 01 - Norfolk

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2017-12-21
Est. Completion 2019-01-18
Phase Phase 2

Sponsor

Atacama Therapeutics

1 total trials

What the Registry Record Tells You About NCT03404570

The ClinicalTrials.gov registry entry for NCT03404570 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atacama Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Palmar Hyperhidrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03404570 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Missouri, Virginia.

Frequently Asked Questions

What is clinical trial NCT03404570 about?

NCT03404570 is a clinical study titled "Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis". This is a pilot exploratory study to evaluate the safety and efficacy of TC-5214 in subjects with palmar hyperhidrosis.

What is the current status of trial NCT03404570?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2017-12-21. Estimated completion is 2019-01-18.

What conditions does trial NCT03404570 study?

This clinical trial studies the following conditions: Palmar Hyperhidrosis.

What interventions are being tested in trial NCT03404570?

The interventions under investigation include: Placebo (OTHER), Dexmecamylamine HCl (DRUG).

Who is sponsoring clinical trial NCT03404570?

This trial is sponsored by Atacama Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03404570 being conducted?

This trial has 3 study locations across California, Missouri, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Palmar Hyperhidrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.